Clinical Trial Detail

NCT ID NCT03531918
Title Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Fred Hutchinson Cancer Research Center
Indications

acute myeloid leukemia

myeloid neoplasm

Therapies

Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin + Mitoxantrone

Cladribine + Cytarabine + Filgrastim

Age Groups: adult senior

No variant requirements are available.